XVIVO strengthens management team

XVIVO Perfusion’s management team is being strengthened in order to ensure a
continued good development of the company. Karin Fischer, who assumes the
position of Marketing and Sales Director Americas, and Pär-Ola Larsson, who
assumes the position of Marketing and Sales Director EMEA, have been recruited
externally. Emur Jensen, Director of Development, and Jenny Wennerberg, Director
of Quality, have been employees at XVIVO Perfusion for three and two years,
respectively.
As of January 1, 2016, XVIVO Perfusion’s management team will consist of six
people, three of whom are stationed in the USA and three in Sweden. This will
increase the company’s presence in the important American market. At the same
time the company’s present global Marketing and Sales Director, Christer de Flon
will go into retirement. He will take on the role of consultant with the task of
developing the Asian market, which the company assesses will develop at an
increasingly fast rate in the future.

Karin Fischer, Marketing and Sales Director for the Americas, has 15 years’
experience of the medical technology industry in several different clinical
areas. Over the past 10 years she has held managerial positions in marketing and
sales as well as quality at companies such as Johnson & Johnson and Getinge.

Pär-Ola Larsson, Marketing and Sales Director for EMEA, has many years’
experience of leading positions in the medical technology industry within sales,
marketing and business development at companies such as Boston Scientific and
Johnson & Johnson. He has been operative in the clinical areas of pulmonology,
gastrology, thorax, sports medicines and neurovascular.

Emur Jensen, Director of Development, has almost 20 years’ experience of leading
positions within the development and manufacturing of medical technology
products. Over the past three years Emur has been responsible for development of
the XPS™. He was previously plant manager at Vitrolife Inc. and before that he
was responsible for technology- and process development at C & MI Inc.

Jenny Wennerberg, Director of Quality Assurance and Regulatory Affairs at XVIVO
Perfusion since 2014. Previously QA/RA Manager at Integrum AB and before that 13
years´ experience with different Quality Assurance and R&D positions within
medical device companies, such as Carmel Pharma.

“These additions to the management team will be an outstanding asset for us in
the work of establishing EVLP with STEEN Solution™ and XPS™ as a standard
treatment for lungs before transplantation. We warmly welcome Karin and Pär-Ola
to XVIVO Perfusion as the roles of Marketing and Sales Director for the Americas
and EMEA, respectively. We are pleased to have an extremely competent management
team comprising such experienced co-workers,” says XVIVO Perfusion’s CEO, Magnus
Nilsson.

December 8, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on December 8, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com